Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).

MLA

Baker, Elizabeth, et al. “Association between Biomarkers of Tobacco Smoke Exposure and Clinical Efficacy of Ivacaftor in the G551D Observational Trial (GOAL).” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, vol. 23, no. 5, Sept. 2024, pp. 959–66. EBSCOhost, https://doi.org/10.1016/j.jcf.2024.07.010.

APA

Baker, E., Harris, W. T., Guimbellot, J. S., Bliton, K., Rowe, S. M., Raju, S. V., & Oates, G. R. (2024). Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL). Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 23(5), 959–966. https://doi.org/10.1016/j.jcf.2024.07.010

Chicago

Baker, Elizabeth, William T Harris, Jennifer S Guimbellot, Kyle Bliton, Steven M Rowe, S Vamsee Raju, and Gabriela R Oates. 2024. “Association between Biomarkers of Tobacco Smoke Exposure and Clinical Efficacy of Ivacaftor in the G551D Observational Trial (GOAL).” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 23 (5): 959–66. doi:10.1016/j.jcf.2024.07.010.